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Abstract.  Previous studies have suggested that the as- 
sembly of fibronectin into the extracellular matrix of 
cultured fibroblasts is mediated by specific matrix as- 
sembly receptors that recognize a  binding site in the 
amino terminus of the fibronectin molecule 
(McKeown-Longo, P. J., and D.  E  Mosher,  1985, J. 
Cell Biol.,  100:364-374).  In the presence of dexameth- 
asone, human fibrosarcoma cells (HT-1080)  acquired 
the ability to specifically bind exogenous plasma 
fibronectin and incorporate it into a detergent-insoluble 
extracellular matrix.  Dexamethasone-induced fibronec- 
tin binding to HT-1080  cells was time dependent, dose 
dependent, and inhibited by cycloheximide. Saturation 
binding curves indicated that dexamethasone induced 
the appearance of 7.7  x  104 matrix assembly receptors 
per cell.  The induced receptors exhibited a  dissocia- 
tion constant (Kt,)  for soluble fibronectin of 5.0  x  10  -8 
M.  In parallel experiments, normal fibroblasts 
exhibited 4.1  x  105 receptors  (KD  =  5.3  ×  10  -8 M) 
per cell. In the presence of cycloheximide, the induced 
fibronectin-binding activity on HT-1080  cells returned 
to uninduced levels within 12 h. In contrast, fibronec- 
tin-binding activity on normal fibroblasts was stable in 
the presence of cycloheximide for up to 54 h.  The 
first-order rate constant (Kt  =  2.07  x  10  -4 min  -1) for 
the transfer of receptor-bound fibronectin to extracellu- 
lar matrix was four- to fivefold less than that for nor- 
mal fibroblasts (Kt  =  1.32  x  10  -3 min-1). 
Lactoperoxidase-catalyzed iodination of HT-1080 
monolayers indicated that a 48,000-mol-wt cell surface 
protein was enhanced with dexamethasone. The results 
from these experiments suggest that dexamethasone in- 
duces functional matrix assembly receptors on the sur- 
face of HT-1080  cells; however, the rate of incorpora- 
tion of fibronectin into the matrix is much slower than 
that of normal fibroblasts. 
F 
mRONECTIN is a prominent plasma protein that is pri- 
marily synthesized by the liver (45).  In the plasma, 
fibronectin is found in a  soluble form as a 440-kD 
disulfide-bonded dimer. An insoluble form of fibronectin is 
found in the extracellular matrix of loose connective tissues, 
basement membranes,  and granulation tissue.  Fibronectin 
may have both structural and adhesive functions in the ma- 
trix. Fibronectin has been shown to bind a number of matrix 
molecules including collagen, heparin/heparan, hyaluronic 
acid, and fibrin and may therefore have a role in the deposi- 
tion and/or organization of these molecules in the matrix. 
When coated onto plastic or glass, fibronectin promotes the 
attachment and spreading of cells. This activity may provide 
fibronectin with the ability to mediate cell-cell and cell-tis- 
sue interactions. In addition, fibronectin can effect a number 
of cellular parameters  including morphology, differentia- 
tion, migration, and proliferation (reviewed in references 24, 
25, and 58). 
In cultured fibroblasts,  the extracellular matrix completely 
surrounds the cells, is insoluble in low ionic strength deter- 
gents and is stabilized by disulfide bonds (8).  Components 
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of the fibroblast matrix that have been identified include 
fibronectin, collagens (types I, III, and VI), thrombospondin 
(8, 18, 19, 27, 48), and proteoglycans (17). Fibronectin in the 
matrix is customarily found in the form of 5-10-nm fibrils 
(9,  12, 13, 18, 26, 51) composed of fibronectin derived from 
both the cells and the serum in which the cells are grown 
(16). Very little is known about precise mechanisms of ex- 
tracellular matrix assembly. Fibronectin is the only matrix 
protein for which a specific, cell-mediated, assembly mecha- 
nism has been described (37-39).  According to this model, 
soluble fibronectin is bound to cell surface receptors (matrix 
assembly receptors), which mediate the transfer of fibronec- 
tin into the detergent-insoluble extracellular matrix. The ma- 
trix assembly receptor recognizes a cell binding site in the 
amino terminus of the fibronectin molecule (39) and is dis- 
tinct from the  140-kD receptor complex (cell  attachment 
receptor) that functions in the attachment of cells to fibronec- 
tin matrices (1, 20, 47). 
In vitro, many transformed cell lines do not contain an ex- 
tracellular fibronectin matrix. This loss has been correlated 
with decreased  fibronectin synthesis (11, 22,  42)  and in- 
creased fibronectin degradation (42).  In some systems, the 
addition of exogenous cellular fibronectin has been shown to 
cause transformed cells to assume a more normal phenotype 
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pears to be related to the inability of the cells to form the ma- 
trix rather than a problem with the quality or quantity of fi- 
bronectin synthesized by the cells (3, 4,  15, 46, 56). Trans- 
formed cells that do not organize a fibronectin matrix are still 
able to attach and spread on fibronectin-coated substrata (15, 
37),  suggesting  that  they  have functional cell  attachment 
(140-kD complex) receptors. The inability of the cells to uti- 
lize the fibronectin from the medium may result from miss- 
ing or defective matrix assembly receptors. Fibronectin ma- 
trix assembly in transformed cells has been  shown to be 
sensitive to glucocorticoids. SV-40 transformed fibroblasts 
can be induced by dexamethasone to organize an extracellu- 
lar matrix containing fibronectin and procollagen (13, 14). 
Dexamethasone also induces an increased rate of fibronec- 
tin synthesis and the assembly of a fibronectin matrix in a 
human fibrosarcoma cell line, HT-1080 (43). In the present 
report,  we  have  used  HT-1080  cells  to  characterize  the 
dexamethasone-induced binding of plasma fibronectin to the 
cell surface and the subsequent assembly of fibronectin into 
the detergent-insoluble matrix. The data indicate that dexa- 
methasone induces functional fibronectin matrix assembly 
receptors on the surface of HT-1080 cells. 
Materials and Methods 
Cell Culture 
Human foreskin fibroblasts were  a  gift  from Dr.  Lynn Allen-Hoffman, 
University of Wisconsin. The cells were cultured in Ham's F-12 nutrient 
medium (Gibeo Laboratories, Grand Island, NY) supplemented with 15 % 
FBS (Sterile Systems, Logan, UT). Human fibrosarcoma cells, HT-1080, 
were a gift from Dr. Noellyn Oliver, The Salk Institute. HT-1080 cells were 
grown in MEM (Gibco Laboratories) supplemented with 10% FBS. All cul- 
tures also contained 100 U/mi penicillin and 50 gg/ml streptomycin. Fibro- 
blasts were plated at 4  x  104 cells/ml and achieved confluence in 5 d. Ex- 
periments were customarily done on cells between passages 4 and 10 and 
1-3 d after the cells reached confluence. HT-1080 cells were plated at 2  x 
104 cells/ml and formed a  monolayer within 4 d.  These cells did not ex- 
hibit contact inhibition of growth and continued to divide,  covering the 
monolayer with round, refractile cells. Experiments were done on cells for 
up to 20 passages on monolayers that had just achieved confluence. 
Dexamethasone (Sigma Chemical Co., St. Louis, MO) was dissolved in 
ethanol, diluted into 10 mi of complete medium (MEM,  10%  FBS), and 
sterile filtered. The concentration was adjusted to 1 x  10  -4 M  with sterile 
PBS. This solution was kept as a  stock and diluted 1:1,000 into complete 
medium for use in HT-1080 ceil cultures. Cultures received dexamethasone 
at 1 x  10  -7 M in complete medium at various times after plating. Specific 
treatment times are as described in the figure legends. 
Cycloheximide (Sigma Chemical Co.)  was dissolved in ethanol at 20 
mg/ml. This stock solution was then diluted  1:1,000 in complete medium 
for use in cell cultures. This concentration (20 gg/ml) was found to inhibit 
>90%  of protein synthesis within  1 h, as measured by incorporation of 
[35S]methionine  into trichloroacetic acid-precipitable radioactivity. 
Purification and Iodination of  Human 
Plasma l~bronectin 
Human plasma fibronectin was purified as described previously (37)  and 
was a gift from Dr.  Deane Mosher, University of Wisconsin. Fibronectin 
(400 gg) was iodinated with 1.0 mCi Na 125I (New England Nuclear, Bos- 
ton, MA) using 40 ~tg of chloramine-T in 0.04 M phosphate buffer, pH 7.4. 
After 60 s, 5 mg of BSA was added to the reaction mixture, and iodinated 
fibronectin was purified on affigel gelatin (Bio-Rad  Laboratories,  Rich- 
mond, CA). Iodinated fibronectin was stabilized by the addition of 1 mg/ml 
of BSA containing 1 mM phenylmethylsulfonyl fluoride, dialyzed against 
PBS and frozen at  -70°C until use. The range of the specific activity of 
~251-fibronectin was from 300-400 ~Ci/mg. Integrity of the labeled protein 
was assessed by autoradiography of an SDS gel containing t25I-fibronectin 
which had been electrophoresed in the presence and absence of reducing 
agent. 
Determination of the Transfer Rate Constant (KO 
for Matrix Assembly 
This constant is based on the endocytic rate constant of Wiley and Can- 
ningham (57).  The transfer rate constant for matrix assembly defines the 
probability of receptor-bound fibronectin (pool I) being transferred into the 
matrix (pool  II)  over a  1-min period,  based on the following equation: 
([FN]n)/([FN]I)  =Ktt, where [FN]I and [FN]n represent the concentration 
of fibronectin in pool I and pool II, respectively, at time t. This equation 
can be solved by a  straight line with a  slope/ft. 
Indirect Immunofluorescence of  Fibronectin in 
Cell Layers 
Cell layers in 35-mm plastic culture dishes were rinsed three times with 
1.0 ml serum-free MEM and fixed for 10 rain with 1.0 ml of 3.5% parafor- 
maldehyde in 0.1 M  phosphate buffer, pH 7.4. After fixation, monolayers 
were rinsed three times with 1.0 ml of PBS. Rabbit antiserum against human 
plasma fibronectin was diluted 1:500 in PBS and incubated on monolayers 
for  1 h  at room temperature. Rabbit antifibronectin was a  gift from Dr. 
Deane  Mosher.  After  staining with  primary  antibody,  cell  layers were 
washed for 30 min with three changes of PBS. Secondary antibody, fluoro- 
isothiocyanate-conjugated goat anti-rabbit IgG (Cooper Biomedical, Inc., 
Cochransville, PA) was diluted 1:100 in PBS and incubated with monolayers 
for 1 h at room temperature. After a second antibody staining, monolayers 
were washed for 30 min with three changes of PBS and viewed under an 
Olympus IMT-2  inverted microscope (Olymus Corporation of America, 
New Hyde Park, NY) equipped with reflected light fluorescence. Controls 
using normal rabbit serum instead of primary antibody showed no fluores- 
cence. 
Binding of uSI-Fibronectin to Cultured Cells 
All binding experiments were done using either F-12 (fibroblasts) or MEM 
(HT-1080)  supplemented with either 5.0%  FBS or 0.2% BSA. In some ex- 
periments medium was supplemented with dexamethasone, 1  x  10  -7 M, 
or cycloheximide, 20 gg/ml. Specific pro~cols are provided in the figure 
legends. Binding medium contained between 350,000-800,000 cpm of ~25I- 
fibronectin per ml. After incubation with labeled medium at 37°C, cultures 
were rinsed four times in cold (4°C) PBS, and cell layers were either se- 
quentially extracted in 1% deoxycholate followed by 4%  SDS or directly 
solubilized in 1.0 N sodium hydroxide. The sequential extraction procedure 
was used to distinguish cell surface-associated radioactivity (deoxycholate 
soluble, pool I) from radioactivity incorporated into the extracellular matrix 
(deoxycholate insoluble, pool II) as previously described (37).  Deoxycho- 
late-soluble and  -insoluble material  were  separated by centrifugation at 
35,000 g  for 30 min. 
Integrity of radioactivity extracted from cell layers was judged by SDS 
gel electrophoresis and autoradiography.  Only intact fibronectin was as- 
sociated with the monolayers. Degradation of ~25I-fibronectin was assessed 
by SDS gel electrophoresis of medium containing labeled protein and by 
quantification of the percentage of labeled protein soluble in 10% trichloro- 
acetic acid. Minimal degradation of labeled protein, 5 % over a 24-h period, 
was observed in the medium conditioned by both cell types. 
To determine specific binding of iodinated preparations, cell layers were 
incubated for  30  min at  37°C with  ~25I-fibmnectin in the absence (total 
binding) or presence (nonspecific binding) of excess unlabeled fibronec- 
tin (350 Ixg/ml).  The range of the specific binding of ~25I-fibronectin was 
60-70%. 
Quantification of  Fibronectin Synthesis 
The amount of fibronectin secreted by the cell monolayers was measured 
in conditioned medium using an ELISA. 96-well microtiter plates were in- 
cubated overnight at  room temperature  with 200  p.l  of purified  human 
plasma fibronectin at 4  p.g/ml in Tris-huffered saline (TBS) j  containing 
0.1%  BSA. Samples to be tested, and fibronectin standard solutions, were 
diluted in PBS containing 5 mM EDTA and 0.5 % Triton X-100. Samples (125 
p.l) were incubated with 125 p.I of rabbit antifibronectin antibody solution 
(competition mixtures). Antifibronectin antibody was diluted  l:10,000  in 
I.  Abbreviation  used in  this paper:  TBS, Tris-buffered saline. 
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overnight at 4°C. After overnight incubation, fibronectin-coated  plates were 
blocked with 1.0% BSA in TBS for 30 rain at room temperature,  and rinsed 
twice for 5 rain with TBS containing 0.05 % Tween-20. Competition mix- 
tures (200 gl) were transferred to coated wells and incubated 2 h at room 
temperature.  Wells were  then washed  twice with TBS containing 0.05 % 
Tween-20, and 200 Ixl of alkaline phosphatase-conjugated  goat anti-rabbit 
IgG diluted 1:1,000  in TBS containing  0.1% BSA was added. Incubation with 
secondary antibody was  for 2  h  at room temperature.  Wells  were then 
washed twice with TBS containing 0.05% Tween-20. Alkaline phosphatase 
substrate was diluted to 1 mg/ml in TBS, pH 9.0, and 200 Ixl was added to 
each well. Color development was measured by Absorbance at 405 nm on 
an E1-307 microtiter plate reader (Bio-Tek Instruments, Inc., Burlington, 
VT). Materials for ELISA  were purchased from Sigma Chemical Co. 
Lactoperoxidase-catalyzed  lodination of  Cell Layers 
HT-1080 cell monolayers in 35-mm plastic tissue culture dishes were rinsed 
four times with 2 ml of MEM at 37°C. Labeling was done in 600 lal of PBS 
containing 5.5 mM glucose,  120 gCi Na ~I, 0.12 U glucosoxidase  (Sigma 
Chemical Co.), and 12 lag of lactoperoxidase  (Sigma Chemical Co.). Iodi- 
Figure 1. Fluorescent staining 
of  the  fibronectin  matrix  of 
dexamethasone-treated  HT- 
1080 cells.  Monolayers of (a) 
HT-1080  cells,  (b)  HT-1080 
cells pretreated for 72 h  with 
10  -7  M  dexamethasone,  and 
(c) fibroblasts were stained for 
extracellular  fibronectin  by 
indirect immunofluorescence. 
Cell  layers  were  fixed  with 
3.0%  paraformaldehyde  and 
stained with rabbit antiserum 
against human  plasma  fibro- 
nectin  (1:500  dilution),  fol- 
lowed  by  a  second  antibody 
staining  using  FITC-conju- 
gated  goat  anti-rabbit  IgG 
(1:100  dilution).  (c-e)  Phase 
contrasts  of  the  same  fields 
shown  in  a-c,  respectively. 
Bars,  20 gm. 
nation was carried out for 10 min at room temperature.  Iodinated  mono- 
layers were rinsed four times with 2 mi of MEM and dissolved into 200-gl 
of gel sample buffer (0.025 M Tris-HC1, pH 6.8, containing 2% SDS, and 
10% glycerol). 
Polyacrylamide  Gel Electrophoresis 
Samples were analyzed by SDS gel electrophoresis on linear (5-16%) poly- 
acrylamide gels using a discontinuous buffer system (32). lodinated proteins 
were visualized by autoradiography  using XAR-5 film (Eastman Kodak Co., 
Rochester,  NY).  Materials for electrophoresis were purchased from Bio- 
Rad Laboratories. 
Results 
Effect of  Dexamethasone on Fibronectin 
Matrix Assembly 
Previous studies have shown that a human fibrosarcoma cell 
line, HT-1080,  synthesizes small amounts of fibronectin and 
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presence  of  1  x  10  -7  M  dexamethasone,  these  cells  in- 
creased their rate of fibronectin biosynthesis, organized a 
fibronectin matrix, and exhibited changes in cellular adhe- 
siveness and morphology (43). The results shown in Fig.  1 
are in agreement with this previous report. In the absence 
of dexamethasone,  HT-1080  cells grew as a  monolayer of 
substrate-attached,  spread  cells.  Within  the  monolayer, a 
clump of rounded, refractile cells was occasionally present 
(Fig.  1 d). These cell layers did not stain for fibronectin by 
indirect immunofluorescence (Fig.  1 a). In the presence of 
1  x  10  -7 M dexamethasone, the HT-1080 cells flattened, ap- 
peared larger, and were less phase dense (Fig. 1 e). The HT- 
1080 cells exhibited an epitheliod morphology rather than 
the elongated, spindle shape typical of fibroblasts (Fig. 1  f). 
After 3 d  in dexamethasone, HT-1080 cells accumulated a 
fibronectin-containing matrix that could be stained by in- 
direct immunofluorescence (Fig.  1 b). The fibronectin was 
in the form of short fine fibrils and in diffuse amorphous pat- 
terns. Fibronectin appeared to be localized to regions of cell- 
cell contact. In contrast, normal fibroblasts exhibited a more 
extensive fibronectin matrix (Fig.  1 c) consisting of longer, 
more well-defined fibrils surrounding the cells. 
The process of dexamethasone-induced fibronectin matrix 
assembly was also followed using ~25I-fibronectin. We have 
previously  shown  that  matrix  assembly  in  cultured  cell 
monolayers can be monitored by the incorporation of ~25I- 
fibronectin into a detergent-insoluble binding pool within the 
cell layer (37-39). Based on data presented in these earlier 
studies, we have proposed that ~25I-fibronectin does not de- 
posit directly into the  extracellular matrix,  but must first 
bind to a detergent-soluble pool (pool I) within the mono- 
layer. Pool I binding is believed to represent specific cell sur- 
face  receptors  (matrix  assembly  receptors).  As  a  conse- 
quence of this binding, fibronectin can then be transferred 
to  a  detergent-insoluble  pool  (pool  II)  which  represents 
fibronectin in the form of extracellular fibrils. 
When HT-1080 cell layers were incubated with 125I-fibro- 
nectin for up to 24 h, no specific binding of t25I-fibronectin 
to  the  cell layers was  observed (Fig.  2  a).  After a  48-h 
pretreatment with dexamethasone, HT-1080 cell layers spe- 
cifically bound  ~25I-fibronectin in  both pool I  and pool II 
(Fig. 2 b). Although dexamethasone restored the ability of 
HT-1080 cells to acquire a fibronectin matrix, accumulation 
of fibronectin in the cell layer represented only 30% of the 
levels incorporated by normal fibroblasts (Fig. 2 c). The ki- 
netics of ~25I-fibronectin binding in pool I  were similar in 
dexamethasone-treated HT-1080 and normal fibroblasts, with 
an apparent steady state being reached between 3 and 6 h; 
however, absolute amounts of fibronectin bound were differ- 
ent.  At  steady state,  normal fibroblast monolayers bound 
2.5-fold more radioactivity in pool I than dexamethasone- 
treated HT-1080 cells. The incorporation of t2sI-fibronectin 
into pool II was linear in both dexamethasone-treated HT- 
1080 cells and fibroblasts. However, fibronectin accumulated 
in pool II at a much slower rate in the HT-1080 monolayers 
over the 24-h period, resulting in fivefold less ~I-fibronec- 
tin incorporated into the matrix of HT-1080 monolayers than 
fibroblast monolayers. 
Because two distinct cell surface receptors for fibronectin 
have been proposed (37, 39), a cell attachment receptor and 
a matrix assembly receptor, it was of interest to determine 
whether the dexamethasone-induced fibronectin binding by 
these cells was a function of induced matrix assembly recep- 
tor activity. Matrix assembly receptors specifically bind a 
70-kD amino-terminal fragment of fibronectin, which binds 
to the receptor but does not become incorporated into the ex- 
tracellular matrix (39). Because this fragment does not con- 
tain the cell attachment domain, it can be used to distinguish 
fibronectin binding to matrix assembly receptors from fibro- 
nectin  binding  to  cell  attachment  receptors.  The  results 
shown in Fig. 2 represent radioactivity that could be com- 
peted for with  excess unlabeled 70-kD  fragment.  Similar 
results were obtained using intact fibronectin as competitor 
(data not shown). A previously described (39) 150-kD frag- 
ment of fibronectin containing the cell attachment, but not 
the matrix assembly site, was unable to compete for the bind- 
ing of t25I-fibronectin to the cell layers (data not shown). 
Therefore, the dexamethasone-induced incorporation of fi- 
bronectin into the detergent-insoluble extracellular matrix of 
HT-1080 cells represented matrix assembly via matrix as- 
sembly receptor activity. 
The effect of the protein synthesis  inhibitor,  cyclohexi- 
mide, on this process was tested to see whether the dexa- 
methasone-induced binding of fibronectin to HT-1080 cells 
required the synthesis of new proteins. In the presence of 20 
0 
0 
x 
u 
Q. 
O3 
HT- 1080 
-DEX 
HT-1080 
+DEX 
0  I 
I~  ~  '  ------ .......  ~  p--~t~ ~  [ 
3  6  24  3  6  24 
Hours 
FIB 
olI 
o  0 ~  s  ~'/  ¢/~// 
f 
/° 
I  I  I 
3  6  24 
Figure 2.  Time  course  of specific 
125I-fibronectin binding  to  HT-1080 
and fibroblast monolayers. Confluent 
cultures  of (a)  HT-1080 cells,  (b) 
HT-1080 cells  pretreated  for 48  h 
with 10  -7 M dexamethasone (DEX), 
and  (c)  fibmblasts  (FIB) were  in- 
cubated with 2.0 ml of MEM con- 
mining 5% FBS and ~25I-fibronectin 
(5  x  l0  s cpm/ml).  Duplicate plates 
received binding medium containing 
the unlabeled 70-kD fragment of fi- 
bronectin  (25  lag/ml). Dexametha- 
sone-treated cells  continued  to  re- 
ceive dexamethasone during the 24-h 
binding period. At the indicated time points, labeled medium was removed and monolayers were processed as described in Materials and 
Methods to determine specific binding of t25I-fibronectin in pool I (open circles) and pool II (solid circles).  Points are the average from 
duplicate plates and represent the radioactivity that could be competed for by the 70-kD fragment. 
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Figure 3. Effect of  cycloheximide on fibronec- 
tin matrix  assembly.  (a) HT-1080 cells were 
pretreated  with  10  -7 M  dexamethasone  for 
48 h in the presence (triangles) or absence 
(circles) of 20 I.tg/ml cycloheximide.  (b) Fi- 
broblasts  were also pretreated  for 48 h with 
cycloheximide.  Initial  plating  densities  were 
adjusted  so that,  at the time  of addition  of 
125I-fibronectin, all monolayers were conflu- 
ent.  After 48-h pretreatment,  monolayers in 
60-ram culture dishes  were  incubated  with 
2.0  ml  of F-12 (FIB)  or MEM  containing 
10  -7  M  dexamethasone  (HT-1080) supple- 
mented  with  5%  FBS  and  ~25I-fibronectin 
(3  x  105 cpm/ml). Cycloheximide treatment 
was continued during the 5.5-h labeling peri- 
od. At the indicated  times,  monolayers were 
rinsed  and binding in pool I (open symbols) 
and pool II (solid symbols) was determined as 
described in Materials  and Methods.  Points 
represent  the average from duplicate  plates. 
lag/ml  cycloheximide,  incorporation of ~25I-fibronectin  into 
dexamethasone-treated HT-1080 cells was inhibited by >70 % 
(Fig. 3 a). This suggested that the synthesis of some protein 
is  important  in  the  binding  of fibronectin  to  these  mono- 
o20  layers. The 30% binding, which was not inhibited, probably  ._ 
reflected nonspecific binding by the monolayers (see Fig. 4).  o  c~ 
In contrast,  normal fibroblasts  showed a  slight increase  in  ~'~ 
125I-fibronectin  binding  in  the  presence  of cycloheximide,  b 
This difference was apparent within 3 h, and became more  ~  15 
lo  pronounced after 5  h  (Fig.  3 b).  Because these cells  were  ,- 
pretreated for 48 h with cycloheximide, any proteins required 
for the assembly of fibronectin into the matrix must be rela-  -~ 
E  I0  o.  tively long-lived on normal fibroblasts. In addition, the syn- 
thesis and accumulation of some protein may decrease the  .~ 
binding of 12sI-fibronectin  to monolayers. Such proteins may  O 
include  endogenous cellular  fibronectin  that may compete 
for the binding of putative matrix assembly receptors on the  uo  5 
surface of these cells, or molecules that bind to fibronectin 
and decrease the affinity of fibronectin for the receptor. 
Kinetics of  Induction and Deinduction 
of Fibronectin Binding 
The kinetics of induction of J25I-fibronectin  binding to HT- 
1080 cells was examined by pretreating monolayers for vari- 
ous  times  with  dexamethasone.  Increased  125I-fibronectin 
binding was seen after 7 h of incubation with dexamethasone 
and a maximum level of binding was achieved after  14 h of 
incubation  (Fig.  4).  At this time,  specific binding was en- 
hanced  10-fold  over  control  levels.  Longer  incubations 
(24-72  h)  resulted  in  binding  levels  that  were  decreased 
20-25 %  from maximum.  A  duplicate  set of plates,  which 
had received cycloheximide, showed no dexamethasone-de- 
pendent  increase  in binding  (Fig.  4).  In fact,  binding was 
slightly  decreased  from control  levels.  Cells  were  treated 
with  dexamethasone  concentrations  ranging  from  10  -s  to 
10  -9 M  and  maximal  fibronectin binding occurred at  1  x 
10  -7 M  (data not shown). 
The deinduction of fibronectin-binding activity was exam- 
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-  cyclohexlmide 
+ cycloheximide 
/ 
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4  8  12  16  26 
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Figure 4.  Time course of induction of receptor activity by dexa- 
methasone.  Monolayers  of HT-1080 cells in 35-ram culture dishes 
were treated with 10  -7 M dexamethasone  (solid circles) for the in- 
dicated times.  A second set of plates also received 20 ~g/ml cyclo- 
heximide  (empty circles). During the last  2 h of dexamethasone 
treatment,  the medium was replaced with 1.0 ml of MEM contain- 
ing 5 % FBS,  10  -7 M dexamethasone,  and ~zsI-fibronectin (5  x  105 
cpm/ml). Cycloheximide treatment was continued during the label- 
ing period. After the 2-h labeling period, the medium was removed, 
and the monolayers were rinsed  and scraped into 1.0 ml of 1.0 N 
sodium hydroxide  for determination  of bound radioactivity.  ~15I- 
Fibronectin,  which bound to monolayers in the presence of excess 
(350 Ixg/ml) unlabeled  fibronectin,  was designated  nonspecific and 
was determined using a duplicate  set  of plates.  Specific  binding 
represents  the difference  between total  and  nonspecific  binding. 
Points represent the mean of  triplicates.  The bars represent the stan- 
dard error of the mean. 
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Figure 5. Time course of dein- 
duction of receptor activity in 
dexamethasone-treated  HT- 
1080 cells. HT-1080  cell mono- 
layers in 35-mm culture dishes 
were pretreated  with  10  -7 M 
dexamethasone  to induce re- 
ceptor  activity.  After  induc- 
tion,  monolayers  were  re- 
moved from dexamethasone- 
containing  medium,  rinsed 
twice with 1.0 ml of complete 
medium,  and  incubated  for 
the  indicated  times  at  37°C 
with  1.0 ml of complete me- 
dium containing no cyclohexi- 
mide  (solid circles)  or  20 
gg/ml  (empty circles) cyclo- 
heximide.  During the last 2 h 
of incubation  in dexamethasone-free  medium,  the  medium was 
replaced  with 1.0 ml of MEM containing 5%  FBS, and usI-fibro- 
nectin (6 x  105 cpm/ml). Those plates that had received cyclohex- 
imide continued to receive it during the 2-h labeling period. After 
the 2-h incubation  with usI-fibronectin,  the medium was removed 
and the monolayers  were rinsed and scraped into  1.0 ml of 1.0 N 
sodium hydroxide for determination of bound radioactivity.  Points 
represent  the mean of triplicate  plates and the standard error of the 
mean is represented  by the bars.  The dashed line represents  125I- 
fibronectin  binding to uninduced HT-1080 monolayers. 
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Figure 6. Time course of induction  of fibronectin synthesis  by dexa- 
methasone in HT-1080 cells. Monolayers of HT-1080 cells in 35-mm 
culture dishes were treated with 10  -7 M dexamethasone  for the in- 
dicated times.  During the last 3 h of dexamethasone  treatment,  the 
medium was replaced with 1.0 ml of MEM containing 5% FBS and 
10  -7 M  dexamethasone.  After the  3-h conditioning period,  the 
medium was removed and assayed for human fibronectin concentra- 
tion by ELISA. Points represent  the mean of triplicates.  Standard 
error of the mean is designated  by the bars. 
ined in cells that were withdrawn from dexamethasone after 
a  24-h  induction  period  (Fig.  5).  When  dexamethasone- 
induced HT-1080 cells were switched to medium containing 
no dexamethasone,  fibronectin-binding activity by the cells 
was slightly diminished over a 12-h period. After 24 h in the 
absence of dexamethasone, fibronectin binding by these cells 
was  still  increased  (35%)  over uninduced  levels  (data not 
shown). In the presence of cycloheximide, fibronectin-bind- 
ing activity was rapidly lost, and returned to uninduced lev- 
els within  12 h. In three separate experiments, the half-time 
required to return fibronectin-binding activity to uninduced 
levels after drug withdrawal, was 20 h. In the presence of cy- 
cloheximide, the half-time was 3.5 h. These results indicated 
that the induced receptor activity required continual protein 
synthesis  for expression.  This  was  in  marked  contrast  to 
results  obtained using cycloheximide-treated normal fibro- 
blasts, where receptor activity was stable for 54 h (Fig. 3 b). 
These data imply that the dexamethasone-induced receptor 
in HT-1080 cells is either lost from the cell surface or ren- 
dered inactive. 
Kinetics of  Induction of Fibronectin Biosynthesis 
Because a previous report indicated that the primary effect 
of dexamethasone  treatment  on  HT-1080 cells  was  an  in- 
crease in the rate of fibronectin synthesis (43), we were in- 
terested in the relationship between the kinetics of induction 
of fibronectin  synthesis and fibronectin-binding  activity in 
these cells. As shown in Fig. 6, the time course of dexarnetha- 
sone-induced  increase  in  fibronectin  synthesis  correlated 
fairly well with the time course of fibronectin-binding activ- 
ity (Fig. 4). The increased rate of fibronectin synthesis was 
detectable  within  9  h  after dexamethasone  treatment,  and 
reached a maximum between  13 and 20 h. At this time, the 
rate of fibronectin biosynthesis (1.31 0g/ml per 3 h) was al- 
most 20 times greater than the uninduced rate (0.07 og/ml per 
3 h), and almost four times the rate of fibronectin synthesis 
in normal fibroblasts (0.38 ~tg/ml per 3 h) (data not shown). 
The increase in fibronectin biosynthetic rate is in agreement 
with a previous report (43).  After 34 h  in dexamethasone, 
the rate of fibronectin biosynthesis had dropped to about half 
of the maximum rate and remained at about this level for the 
next  18 h. 
Saturation Binding of Fibronectin to 
Dexamethasone-induced HT-1080 Cells 
The  effect  of increasing  concentrations  of fibronectin  on 
binding to both dexamethasone-induced HT-1080 and normal 
fibroblasts was tested.  Saturable binding was demonstrated 
in both systems, with half-maximal binding being achieved 
with about 10 Ixg/ml fibronectin (Fig. 7). HT-1080 cells that 
were not treated with dexamethasone showed no concentra- 
tion  dependence  of fibronectin  binding  (data  not  shown). 
These data were replotted for Scatchard analysis (inset) and 
binding constants and receptor number per cell were deter- 
mined. The dexamethasone-treated HT-1080 cells contained 
7.7  x  104  receptor  sites  per  cell.  The  induced  apparent 
receptor had a dissociation constant (KD) for fibronectin of 
5.03  ×  10  -8  M.  Normal  fibroblasts  contained  4.1  x  105 
receptor  sites  per  cell.  The  KD  for the  normal  fibroblast 
receptor  for  fibronectin  was  5.34  x  10  -s  M.  These  data 
were consistent with  a  single class of receptor.  Therefore, 
dexamethasone-induced HT-1080 cells contain fivefold fewer 
receptors  than  normal  fibroblasts;  however,  the  induced 
receptors have the same affinity for fibronectin as the recep- 
The Journal of Cell Biology, Volume  104,  1987  606 40 
o 
2o 
o  HT-1080 
+ DEX 
K  = 5.03xlO'eM 
~_  77,000 Iltes 
o~.  ~ 
~ 21 "'~... 
2  6  I0 
B(MxlO") 
/  -/ 
t 
I  I 
12  24 
b  Ft8 
KO=  5,34xlO-IM 
~012  41:£000 llltel 
a~  "% 
4  I  l~ 
2040  60 
B (MxlO u  ) 
./ 
,oo  J  / 
/ 
I  ]  ]  I  I 
36  12  24  36  48 
/,tg/ml  Fibronectin 
Figure 7.  Saturation  curve and Scatchard analysis  of fibronectin 
binding to (a) dexamethasone-treated  HT-1080 monolayers and (b) 
fibroblast  monolayers.  HT-1080 cells  were  treated  with  10  -7  M 
dexamethasone 18 h before incubation with 125I-fibronectin. Mono- 
layers  in 35-mm culture dishes were incubated  for 3 h in MEM 
containing  10  -7 M  dexamethasone  (HT-1080) or F-12 (FIB)  con- 
mining 0.2% BSA, t25I-fibronectin (7 x  105 cpm/ml), and increas- 
ing concentrations of unlabeled fibronectin.  After 3 h, monolayers 
were washed and scraped into 1.5 ml of 1.0% deoxycholate  for de- 
termination of pool I binding.  Data were analyzed by the method 
of Scatchard (insets) and fitted with a straight  line (r =  0.91 [a], 
r  =  0.95  [b]) to determine dissociation constants  (KD) and recep- 
tor number (sites). 
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Figure 8.  Transfer  rate constant for fibronectin  matrix assembly. 
Confluent  monolayers,  in 35-ram culture dishes,  of (a) HT-1080 
cells and (b) fibroblasts  were incubated  with 1.0 ml of MEM con- 
mining  10  -7 M  dexamethasone  (HT-1080) or 1.0 ml of F-L2 (FIB) 
supplemented  with 5 % FBS and 12sI-fibronectin  (8  x  105 cpm/ml). 
HT-1080 cells  were pretreated  for 48 h with  10  -7 M  dexametha- 
sone. Monolayers were incubated at 37°C for the indicated amount 
of time and binding in pool I (open circles) and pool II (solid cir- 
cles) was determined as described in Materials  and Methods.  The 
transfer rate constant (Kt) was derived  from the slope of the line (r 
-- 0.98) of the ratio of fibronectin binding in pool II/pool I plotted 
as a function of time (inset). 
tors from normal fibroblasts.  Similar results were obtained 
in  parallel  experiments  using  the  amino-terminal  70-kD 
fibronectin fragment (40). 
Kinetics of  Fibronectin Transfer into the Matrix 
Previous studies (37, 39) have shown that the incorporation 
of exogenous plasma fibronectin into the extracellular matrix 
proceeds  in  a  stepwise  fashion  where  fibronectin  is  first 
bound to cell  surface  receptors  (pool I) and  subsequently 
transferred  to  a  detergent-insoluble  extracellular  matrix 
(pool II). This implies that the rate of fibronectin accumula- 
tion in pool II depends both on the concentration of fibronec- 
tin  bound  in  pool  I  and  the  rate  at  which  pool  I-bound 
fibronectin  is  transferred  into  pool  II.  As  outlined  in 
Materials  and  Methods,  the  rate  of transfer  of receptor- 
bound fibronectin into the matrix can be described by a trans- 
fer rate constant, Kt, which measures the probability of re- 
ceptor-bound fibronectin being  transferred  into the matrix 
over a  1-min period.  Kt determinations  for both fibroblasts 
and dexamethasone-treated  HT-1080 cells were determined 
over a 6-h period (Fig.  8).  As shown in the inset of Fig.  8, 
the Kt  for dexamethasone-induced  HT-1080 cells  was 2.07 
×  10  -4 min  -1.  The KI  for normal  fibroblasts  was  1.32  × 
10  -3 min-L  These results  indicated that once fibronectin is 
bound to the receptor, the HT-1080 cells are five- to sixfold 
less efficient than normal cells in transferring receptor-bound 
fibronectin into the matrix. 
Dexamethasone-induced Cell Surface Proteins 
The effect of dexamethasone  on cell  surface proteins  was 
analyzed by lactoperoxidase-catalyzed iodination. In several 
experiments,  only one cell surface protein was consistently 
enhanced after treatment with dexamethasone.  This protein 
had an apparent molecular mass of 48,000 (Fig. 9), and was 
enhanced fivefold over uninduced levels as judged by den- 
sitometric scanning of the autoradiograph.  A  protein of the 
same molecular mass on the surface of normal fibroblasts 
was also iodinated (data not shown).  The relative mobility 
of  the 48-kD protein was unchanged in the presence of reduc- 
ing agent,  indicating  that this  protein  was not involved in 
disulfide-bonded complexes, nor did it contain extensive in- 
tramolecular disulfde bonding (data not shown). 
Discussion 
Previous studies have shown that glucocorticoids can induce 
the formation of a  fibronectin-containing extracellular  ma- 
trix in some transformed cell lines (6,  13,  14, 43).  In some 
cases, this was accompanied by increased cell flattening and 
adhesion (6, 43).  Similar results have been reported in cul- 
tured  rat  hepatocytes  (36),  where  dexamethasone  also  in- 
creases the rate of insulin receptor synthesis (50).  Both an 
increased rate of fibronectin biosynthesis and changes in cell 
surface molecules have been postulated as possible mecha- 
nisms  involved  in  mediating  the  phenotypic  changes  ob- 
served with glucocorticoid treatment.  Glucocorticoid-induced 
increases  in  levels  of fibronectin  biosynthesis  have  been 
demonstrated in the human fibrosarcoma cell line, HT-1080 
(43),  and in a rat hepatoma cell line (7) as well as normal 
fibroblasts (34, 43).  In the HT-1080 cells the increased rate 
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iodinated  cell  surface  mole- 
cules from HT-1080  monolay- 
ers. HT-1080 cell monolayers 
were  either  (a)  untreated or 
(b)  pretreated  for 24 h  with 
10  -7 M dexamethasone before 
lactoperoxidase-catalyzed io- 
dination. Cell layers were dis- 
solved  in  gel  sample buffer 
reduced  with  2.0% I]-mer- 
captoethanol, boiled, and elec- 
trophoresed  into  linear  (5- 
16%)  polyacrylamide  gels. 
After electrophoresis  gels were 
fixed and dried  and radioac- 
tive bands were visualized by 
autoradiography. Slashes indi- 
cate molecular mass standards. 
Arrow  indicates  the  48-kD 
dexamethasone-sensitive pro- 
tein. 
of fibronectin synthesis was accompanied by deposition of 
fibronectin into the extraceUular matrix. 
In a series of previous reports (37-41) we have proposed 
that the deposition of soluble fibronectin into the extracellu- 
lar matrix of cultured fibroblasts is mediated by the action 
of specific cell surface receptors, which we have termed ma- 
trix assembly receptors. These receptors recognize a binding 
site  in  the  amino  terminus  of the  fibronectin  molecule, 
termed the matrix assembly site.  In the present study, we 
have confirmed the dexamethasone-induced increase in fi- 
bronectin synthesis and have provided evidence for the in- 
duction of specific fibronectin-binding molecule(s), matrix 
assembly receptors on the surface of these cells. 
The induction of fibronectin-binding activity by dexameth- 
asone in HT-1080 cells was dose dependent, time dependent, 
and inhibited by cycloheximide; suggesting that fibronectin 
binding required de novo protein synthesis. Specific binding 
of fibronectin to induced receptors was completely inhibited 
by a 70-kD fibronectin fragment containing the amino-termi- 
nal one-third of the molecule. This fragment binds to matrix 
assembly receptors and not to cell attachment receptors (39). 
Therefore, the induced receptors appeared to be receptors for 
fibronectin matrix assembly and not receptors for cell attach- 
ment. HT-1080 cells apparently contained functional cell at- 
tachment receptors, because they attached and spread nor- 
mally  on  fibronectin-coated substrata  (37).  The  induced 
receptor activity on HT-1080 ceils exhibited equivalent bind- 
ing affinity for fibronectin as the receptor on normal fibro- 
blasts,  Ko  =  5.0  x  10  -8 M.  However, HT-1080 cells con- 
rained  fivefold fewer (77,000)  receptor sites  as  compared 
with fibroblasts (410,000). The decreased number of receptor 
sites may be a consequence of the dexamethasone-induced 
receptor having a  very short half-life on the cell surface. 
Fibronectin-binding activity on normal fibroblasts was stable 
for 54 h in the presence of cycloheximide, suggesting that the 
half-life of the receptor was on the order of several days.  In 
contrast,  the  dexamethasone-induced  fibronectin-binding 
activity had an apparent half-life of only 3.5 h in the presence 
of cycloheximide, indicating that either the receptor or some 
protein required for its activity had a very short half-life. The 
reason for this short half-life is not known. Transformed cells 
are known to be more proteolytically active than their non- 
transformed counterparts (3). It is possible, therefore, that 
receptor activity may be sensitive to proteolysis. However, 
the receptor activity of normal fibroblasts and induced HT- 
1080  cells  was  insensitive to  mild  trypsinization (unpub- 
lished  observations).  Transformed  cells,  including  some 
clones of HT-1080 cells, are known to synthesize increased 
amounts of plasminogen activator (30), and dexamethasone 
has been shown to induce an inhibitor of  plasminogen activa- 
tor in hepatoma cells (10). Therefore, dexamethasone could 
have a stabilizing effect on a plasmin-sensitive receptor. This 
seems unlikely because ~5I-fibronectin, a plasmin-sensitive 
protein (28), was stable in the medium of HT-1080 cell cul- 
tures for at least 24 h  (unpublished observations). Alterna- 
tively, the unstable association of the induced receptor with 
the cell surface could result from a defect in either the recep- 
tor itself or another molecule (membrane or cytoskeletal) re- 
quired for receptor activity. 
The kinetics of binding of fibronectin to the dexametha- 
sone-induced receptor (pool I binding) were similar to those 
obtained using normal fibroblasts. However, once fibronec- 
tin was bound to the receptors, its rate of transfer (K,) into 
the extracellular matrix was fivefold lower than that of nor- 
mal  fibroblasts.  Therefore,  when  compared  with  normal 
fibroblasts,  the slower rate of accumulation of fibronectin 
into the matrix of dexamethasone-treated HT-1080 cells (Fig. 
2)  resulted  from decreased  fibronectin binding  in  pool  I 
(fewer receptors) and slower transfer of receptor-bound fi- 
bronectin into pool II (lower Kt).  This difference was also 
reflected in the immunofluorescent staining patterns (Fig. 1), 
which showed that a relatively small proportion of the fibro- 
nectin in the matrix of dexamethasone-induced HT-1080 cells 
was in the form of fibrils, as compared with normal. The rea- 
son for the lower transfer rate constant in HT-1080 cells is not 
known. In fact, very little is known about the processes in 
normal fibroblasts that render fibronectin detergent insolu- 
ble. Once bound to the receptors, fibronectin molecules can 
form disulfide-bonded aggregate structures through intramo- 
lecular disulfide exchange within their amino termini (38). 
This process may be important in fibronectin-forming fibrils 
and in becoming detergent insoluble. In addition, a number 
of forces may regulate the formation and  organization of 
fibronectin fibrils,  including cell surface gangliosides  (31, 
52, 53,  59), the cytoskeleton (35), and other matrix mole- 
cules (29,  49).  Molecules representing all these categories 
have been shown to be altered during transformation (4). Al- 
ternatively, the decreased rate of fibronectin transfer into the 
extracellular matrix of HT-1080 cells may reflect differences 
in the cell cycle between normal fibroblasts, which are con- 
tact inhibited, and HT-1080 cells, which are actively divid- 
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fibronectin matrix than cells that are growth arrested (23). 
Using lactoperoxidase-catalyzed iodination of cell mono- 
layers we have identified only one cell surface protein that 
is enhanced after treatment with dexamethasone. This pro- 
tein has a molecular mass of 48,000. The dexamethasone-in- 
duced 48-kD protein on the surface of the HT-1080 cells may 
be related to a 47/48-kD  cell surface protein described by 
others. Such a protein has been identified on the surface of 
baby hamster kidney (BHK) cells, and has been implicated 
in mediating the spreading of these cells on fibronectin (5, 
21).  In one study (5), this protein was preferentially cross- 
linked  to  fibronectin  during  attachment  and  spreading  of 
BHK cells to fibronectin-coated glass coverslips. Antibodies 
prepared  against a  fraction enriched for this protein were 
subsequently shown to block spreading,  but not initial at- 
tachment of cells to fibronectin (21). In a second study, anti- 
bodies  prepared  against BHK  cell  wheat germ  agglutinin 
receptors  caused  rounding and  detachment  of cells  from 
fibronectin substrata.  This  study  suggested that a  trypsin- 
resistant 48-kD  cell  surface  protein  was  important in the 
adhesion of cells  to fibronectin (44).  A  recent report has 
identified a similar class  of cell surface antigen on murine 
3T3 and L929 cells  (55).  In addition, a 47-kD fibronectin- 
binding  molecule  has  been  identified  in  cultured  human 
fibroblasts  (33). 
The function of the dexamethasone-sensitive 48-kD pro- 
tein on the surface of HT-1080 cells is not known. It is in- 
duced on the cell surface within 14 h and is lost from the sur- 
face during a  10-h chase, where it is recovered, apparently 
intact, from the conditioned medium (unpublished observa- 
tions). The kinetics of 48-kD induction and loss are similar 
to those shown for fibronectin binding, suggesting that this 
molecule may be involved in the binding of soluble fibronec- 
tin to cell surfaces. Alternatively, the 48-kD protein may play 
a role in the dexamethasone-induced spreading of these cells 
and may accumulate in the cell layer secondary to the deposi- 
tion of a fibronectin matrix. A third possibility is that the as- 
sembly of the extracellular matrix is coupled to the process 
of cell spreading and that the 48-kD  protein is involved in 
both processes.  A recent report using variants  of a ganglio- 
side-deficient cell line have correlated the expression of com- 
plex gangliosides with the ability of these variant cell types 
to organize fibronectin into extracellular fibrils (52). These 
authors have postulated that the matrix  assembly  receptor 
may be a complex ganglioside. Consistent with this hypothe- 
sis, Thompson et al. (54) have identified a ganglioside-bind- 
ing site in the amino terminus of fibronectin (54). Because 
these  studies  were  performed  using  a  fibronectin-binding 
subset of oligosaccharides purified from brain gangliosides, 
the physiological significance of this binding remains to be 
determined. However, it does appear that the ability of cells 
to organize a fibronectin matrix may require the proper set 
of interactions among several  cellular structures  including 
the cell surface and the cytoskeleton. 
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